The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

The European Medicines Agency's (EMA) safety committee has concluded that a potentially dangerous eye condition is a very ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

US woman Caroline Davis shared incredible before and after images of her weight loss after using semaglutide drug Wegovy.

The European Medicines Agency’s safety committee said on Friday Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.

Omada Health is making its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.